It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...
Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...
Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
EST Cathie Wood’s ARK Investment bought 178.1K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...
The CRISPR molecular scissors have the potential to revolutionize the treatment of genetic diseases. This is because they can ...